Key clinical point:
Major finding: Hazard ratios for poor survival were 1.33 for scores of 3-4 and 2.31 for scores of 5 or greater, compared with 1.0 and 1.127 for scores of 0 or 1-2, respectively.
Study details: A review of 4,083 patients from the CIBMTR database.
Disclosures: Dr. Broglie reported having no financial disclosures.
Source: Broglie L et al. BMT Tandem Meeting, Abstract 16.
Broglie L et al. BMT Tandem Meeting, Abstract 16.
This Week's Must Reads
Apixaban surpasses DOACs in very elderly patients, Deitelzweig SB et al. Circulation. 2018 Nov 6;138[suppl 1]:A14900
Sickle cell: Daily hydroxyurea safe in African children, Tshilolo L et al. ASH 2018, Abstract 3
Study supports long-term survival in multiple myeloma subgroup, Usmani SZ et al. Blood Cancer J. 2018 Nov 23;8(12):123
Similar VTE rates seen with tofacitinib, TNF inhibitors, Desai RJ et al. Arthritis Rheumatol. 2018;70(suppl 10), Abstract L09
Recurrence risk high regardless of VTE classification, Albertsen IE et al. Am J Med. 2018 Sep;131(9):1067-74.e4
Must Reads in Cellular Therapy
HSCT performs well in scleroderma-related lung disease, Goldin J et al. Arthritis Rheumatol. 2018;70(Suppl 10): Abstract 901
Immune system changes play a role in AML relapse, Christopher MJ et al. N Engl J Med. 2018 Oct 31. doi: 10.1056/NEJMoa1808777.
Auto-HSCT plus ablation in severe scleroderma, Sullivan KM et al. ACR Annual Meeting, Abstract 1820
CAR T induced resistance in ALL, Ruella M et al. Nat Med. 2018 Oct 1. doi: 10.1038/s41591-018-0201-9
auto-FMT could help ease GVHD after transplant, Taur Y et al. Sci Transl Med. 2018 Sep 26. doi: 10.1126/scitranslmed.aap9489